Resources

Antimicrobial Stewardship and Resistance

Business Case

Asymptomatic bacteriuria

Position Statement

AMMI Canad a position statement on asymptomatic bacteriuria

Resources

Cannabis

Statement from the Chief Public Health Officer Health Professional Forum Cannabis Toolkit to Educate Health Professionals

Déclaration du Forum des professionnels de l’administratrice en chef de la santé publique sur la nouvelle trousse d’outils sur le cannabis destinée aux professionnels de la santé

AFN National First Nations Cannabis Summit (March 28-29, 2019) (English | Français)

Canadian Antimicrobial Resistance Surveillance System (CARSS)

The Canadian Antimicrobial Resistance Surveillance System (CARSS) Report – 2020 is now available on the Government of Canada website.

The CARSS report provides an integrated picture of antimicrobial resistance (AMR) and antimicrobial use (AMU) in Canada, prioritizing data acquired by the Public Health Agency of Canada (PHAC) and its partners. Web links to this year’s report will be circulated shortly.

This year’s report provides details on AMR in organisms of highest concern to Canadians, as well as information on AMU in human and animal populations. In summary:

There are indications that the AMR landscape is worsening in humans.
AMU continues to increase in humans, particularly in elderly Canadians.
Despite overall declines, the quantities of antimicrobials sold for use in animals increased between 2017 and 2018.

The growing trend of AMR is a problem that no entity can solve on its own. We look forward to the continued and improved integration of AMR and AMU data from all PHAC partners, as we collaboratively work towards limiting the rise of AMR infections in Canada.

https://www.canada.ca/en/public-health/services/publications/drugs-health-products/canadian-antimicrobial-resistance-surveillance-system-2020-report.html

Chief Public Health Officer (CPHO)

Chief Public Health Officer of Canada spotlight report on Handle with Care: Preserving Antibiotics Now and Into the Future.

This report highlights the social and cultural drivers of the unnecessary prescribing and improper use of antibiotics in Canada and describes what Canadians, health care providers, and health system leaders can do to reduce inappropriate antibiotic use and conserve their effectiveness.

Influenza

Lyme Disease

Position Statement

Resources

NEW Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis

NEW: The internet can be a valuable source of information; it can also be difficult sometimes to tell what information is backed up by good science. Here are some reliable sites that can help answer your questions:

Federal Framework

Lyme Disease in Canada – A Federal Framework (English French)
AMMI Canada’s response to the Draft Federal Framework on Lyme Disease

Surveillance

Surveillance for Lyme disease in Canada: 2009–2015 – Canada.ca (English | Français)

National Advisory Committee on Immunization (NACI)

National Advisory Committee on Immunization (NACI): Statements and publications

NACI makes recommendations for the use of vaccines currently or newly approved for use in humans in Canada, including the identification of groups at risk for vaccine-preventable diseases for whom vaccination should be targeted. NACI knowledge syntheses, analyses and recommendations on vaccine use in Canada are published in literature reviews, statements and updates.
New statements are those which have been published within the past five years. Previous statements are those which are were published over five years ago and have been archived.

NACI recommendations are also published in vaccine-specific chapters of the Canadian Immunization Guide.